Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeCALM
2025-521093-34-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF) comparing Adcetris maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival at 2 years. Planned start Aug 2025; status: authorised.
02
Drugs
brentuximab vedotin
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2025-521093-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521093-34-00.